Caroline A Owen or C Owen
Harvard University
H-index: 51
North America-United States
Top articles of Caroline A Owen or C Owen
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Loss of ADAM15 in female mice does not worsen pressure overload cardiomyopathy, independent of ovarian hormones | American Journal of Physiology-Heart and Circulatory Physiology | Vidhya Krishnan Nikki Atanasova Preetinder K Aujla Devon Hupka Caroline A Owen | 2024/4/12 |
Maternal Smoke-Induced Low CC16 Expression Is Associated With Impaired Alveologenesis and Lower Lung Function in Adulthood | JJ Rojas-Quintero AS Colborg G Seedorf JT Kue TD Wu | 2024/5 | |
Validation of Estrogen-responsive Tissue Inhibitor of Metalloproteinases-1 as a Sex-specific Biomarker for Acute Lung Injury | S Almuntashiri S Dutta Y Zhu G Ramírez V Irineo-Moreno | 2024/5 | |
A First-in-human Study in Healthy Volunteers Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5055, A Novel Oral Porcupine Inhibitor Under … | CA Owen X-H Zhou O Sobande N Ferrari K Hezaveh | 2024/5 | |
CC16 augmentation reduces exaggerated COPD-like disease in Cc16-deficient mice | JCI insight | Joselyn Rojas-Quintero Maria Eugenia Laucho-Contreras Xiaoyun Wang Quynh-Anh Fucci Patrick R Burkett | 2023/3/3 |
Hyperkalemia is an underestimated risk factor in COPD: a retrospective study from two Phase 3 trials | Jukka Mäenpää Isobel Anderson Caroline A Owen Ulrika Emerath Rod Hughes | 2023/9/9 | |
Loss of ADAM15 exacerbates transition to decompensated myocardial hypertrophy and dilation through activation of the calcineurin pathway | Hypertension | Preetinder K Aujla Mei Hu Bridgette Hartley Joshua W Kranrod Anissa Viveiros | 2023/1 |
Evaluation of ACCEPT to predict COPD exacerbations in NOVELTY | Samuel Lewis Adam Taylor Eleni Rapsomaniki Hana Müllerová Cecilia Kristensson | 2023/9/9 | |
Loss of A Metalloproteinase and Disintegrin 15 leads to exacerbated myocardial hypertrophy and dilation through activation of the calcineurin pathway in male but not female micev | Preetinder Aujla Mei Hu Joshua Kranrod Anissa Viveiros Tolga Kilic | 2023/5/23 | |
Extracellular vesicle-encapsulated CC16 as novel nanotherapeutics for treatment of acute lung injury | Molecular Therapy | Yohan Han Yin Zhu Sultan Almuntashiri Xiaoyun Wang Payaningal R Somanath | 2023/5/3 |
ADAM15 is required for optimal collagen cross-linking and scar formation following myocardial infarction | Matrix Biology | Michael Chute Preetinder K Aujla Yingxi Li Sayantan Jana Pavel Zhabyeyev | 2022/1/1 |
Serine Proteinases: Overview☆ | Caroline A Owen | 2022 | |
Dysregulation of miR-103a mediates cigarette smoking–induced lipid-laden macrophage formation | American Journal of Respiratory Cell and Molecular Biology | Yin Zhu Yohan Han Sultan Almuntashiri Saugata Dutta Xiaoyun Wang | 2022/12 |
Cc16 Deficiency Is Associated with Impaired Lung Development in Offspring Exposed to Perinatal Cigarette Smoke | JJ Rojas-Quintero Q-A Fucci ME Laucho CA Owen F Polverino | 2022/5 | |
Association of clonal hematopoiesis with chronic obstructive pulmonary disease | Blood, The Journal of the American Society of Hematology | Peter G Miller Dandi Qiao Joselyn Rojas-Quintero Michael C Honigberg Adam S Sperling | 2022/1/20 |
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation | Journal of Cystic Fibrosis | Edward F McKone Emily A DiMango Sivagurunathan Sutharsan Tara Lynn Barto Daniel Campbell | 2021/3/1 |
Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND … | The Lancet Respiratory Medicine | Patrick A Flume Reta Fischer Biner Damian G Downey Cynthia Brown Manu Jain | 2021/7/1 |
A disintegrin and metalloproteinase domain-15 deficiency leads to exaggerated cigarette smoke-induced chronic obstructive pulmonary disease (COPD)-like disease in mice | Mucosal immunology | Xiaoyun Wang Joselyn Rojas-Quintero Duo Zhang Takahiro Nakajima Katherine H Walker | 2021/3 |
Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label … | The Lancet Respiratory Medicine | Mark A Chilvers Jane C Davies Carlos Milla Simon Tian Zifei Han | 2021/7/1 |
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with … | Journal of Cystic Fibrosis | Jane C Davies Isabelle Sermet-Gaudelus Lutz Naehrlich R Scott Harris Daniel Campbell | 2021/1/1 |
